Important Safety Information
ACIPHEX has a well-established safety profile. The most common side effect possibly related to ACIPHEX is headache. Symptom relief does not rule out other serious stomach conditions. Patients on warfarin (such as Coumadin(R)) may need to be monitored more closely by their doctor. To learn more, talk to your doctor and see the full product information at http://www.aciphex.com.
About Eisai Corporation of North America
Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.
Eisai Corporation of North America supports the activities of its
operating companies in North America. These operating companies include:
Eisai Research Institute of Boston, Inc., a discovery operation with strong
organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical
company specializing in the development of therapeutic monoclonal
antibodies; Eisai Medical Research Inc., a clinical development group;
Eisai Inc., a commercial operation with manufacturing and marketing/sales
functions; MGI PHARMA, INC., an R&D and commercial operation with
manufacturing and marketing/sales functions; and Eisai Machinery U.S.A.,
which markets and maintains pharmaceutical manufacturing machinery.
For more information about Eisai, please visit http://www.eisai.com.
ACIPHEX is a registered trademark of Eisai Co., Ltd.
Coumadin is a registered trademark of Bristol-Myers Squibb Pharma Company.
For Media Inquiries: For Investor In
|SOURCE Eisai Corporation of North America|
Copyright©2008 PR Newswire.
All rights reserved